Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity
Open Access
- 1 March 2014
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 88 (1) , 58-65
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK PhD Studentship
- Cancer Research UK Centre and Programme Awards
This publication has 35 references indexed in Scilit:
- Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivativesOrganic & Biomolecular Chemistry, 2012
- Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombinationCancer Chemotherapy and Pharmacology, 2011
- Phosphorylation of p50 NF-κB at a Single Serine Residue by DNA-dependent Protein Kinase Is Critical for VCAM-1 Expression upon TNF TreatmentJournal of Biological Chemistry, 2010
- DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progressionBMC Molecular Biology, 2010
- A Role of DNA-PK for the Metabolic Gene Regulation in Response to InsulinCell, 2009
- DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic LeukemiaClinical Cancer Research, 2008
- Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441Cancer Research, 2006
- Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone librariesBioorganic & Medicinal Chemistry Letters, 2004
- The DNA‐dependent protein kinase: the director at the endImmunological Reviews, 2004
- Binding of the DNA-dependent protein kinase catalytic subunit to Holliday junctionsBiochemical Journal, 2004